Home » Legalaxy » Legalaxy – Monthly Newsletter Series – Vol XIII – June, 2024

DISCLAIMER: The material contained in this publication is solely for information and general guidance and not for advertising or soliciting. The information provided does not constitute professional advice that may be required before acting on any matter. While every care has been taken in the preparation of this publication to ensure its accuracy, Vaish Associates Advocates neither assumes responsibility for any errors, which despite all precautions, may be found herein nor accepts any liability, and disclaims all responsibility, for any kind of loss or damage arising on account of anyone acting / refraining to act by placing reliance upon the information contained in this publication.

In the June edition of our monthly newsletter “Legalaxy”, our team analyses some of the key developments in securities market, banking and finance, renewable energy and pharmaceuticals.

Below are the key highlights of the newsletter:

  • Rumour verification in 24 hours – SEBI notifies industry standards and framework
  • SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2024 – Notified
  • SEBI revises the ICDR Regulations relating to minimum promoter contribution
  • Insider trading – unverified information cannot be ‘generally available information’
  • NISM certificate mandated for a member of key investment team of an AIF manager
  • SEBI relaxes KYC norms to simplify risk management framework
  • Introduction of framework for administration of research analysts and investment advisers
  • SEBI simplifies digital onboarding for clients of Portfolio Managers and boosts transparency with disclosures
  • SEBI mandates registration for distributors of portfolio management services with APMI
  • Regularization of partly paid units by AIFs to persons resident outside India by RBI
  • RBI amends the Foreign Exchange Management (Deposit) Regulations, 2016
  • Boost to green hydrogen production: renewable energy plants exempted from RLMM and ALMM
  • Department of Pharmaceuticals mandates self-declarations by ethics committees for UCPMP compliance

We hope you like our publication. We look forward to your suggestions.

Please feel free to contact us at [email protected]